How Vaping Became Big Tobacco’s New Nicotine Trap, Part 2 of 2

In Part 1 of this series, we examined how the cigarette business evolved into a nicotine business. The warning labels came. The science became clearer. The public slowly began to understand that the real trap was not only smoking itself, but the addictive grip of nicotine at the center of it all. Once that truth became harder to deny, the nicotine economy did not disappear. It adapted.

That adaptation is one of the most important consumer health stories of the modern era.

Vaping did not erase the nicotine problem. It modernized it.

The device changed. The smoke became aerosol. The packaging became cleaner, sleeker, more technological, and often more socially acceptable to a new generation of users. But the underlying commercial logic remained painfully familiar: keep nicotine in the bloodstream, keep the dependency alive, and keep the customer in the cycle.

That is why the vaping story must be understood not as a completely separate chapter from cigarettes, but as the continuation of the same nicotine story in a new form.

The public health concern is not speculative. The Centers for Disease Control and Prevention states plainly that “No tobacco products, including e-cigarettes, are safe” and that “Most e-cigarettes contain nicotine, which is highly addictive.”[1] That language matters because it cuts through the marketing fog. For years, vaping was often discussed in softer, more ambiguous terms, as though it represented some clean break from the old tobacco problem. But nicotine remained central. The delivery system changed. The chemical dependency did not.

And in some ways, the modern delivery system may be even more effective at embedding nicotine into daily life.

Traditional cigarette use was at least visible. It came with smoke, smell, social stigma, and obvious limits on where and when it could be used. Vaping reduced much of that friction. Devices became discreet. Use became easier to conceal. Sessions could become shorter, more frequent, and more constant throughout the day. In practical terms, that means the behavioral loop around nicotine can become even more deeply integrated into routine life. The user is no longer limited to the ritual of stepping outside for a cigarette. The habit can follow them nearly everywhere.

That matters because addiction is not merely chemical. It is behavioral. It attaches itself to moments, routines, stress, boredom, driving, socializing, and repetition. A nicotine delivery system that is easier to use more often is not merely a new product. It is a more adaptable dependency platform.

The youth data makes this even more troubling.

The CDC states that “E-cigarettes are the most commonly used tobacco product among U.S. youth.”[2] In 2024, the agency reported that 1.63 million U.S. middle and high school students currently used e-cigarettes.[2] That is not a small niche issue. It is evidence that the nicotine economy successfully migrated into a new demographic with a new device. And the CDC adds another deeply important point: “Most middle and high school students who vape want to quit.”[2] That line should stop any reader in their tracks. It means the problem is not simply youthful experimentation or preference. It means many young users are already inside a dependency cycle they do not want to remain in.

The danger is not limited to present use alone. The CDC also notes that nicotine can harm the parts of an adolescent brain that control attention, learning, mood, and impulse control, and warns that youth can begin showing signs of addiction quickly.[1] This is precisely what makes the vape story so serious. It is not merely about replacing one product with another. It is about introducing a highly addictive substance through a format that can be frequent, discreet, flavored, and behaviorally sticky at an earlier stage of life.

There is also the broader health question. The CDC states that e-cigarette aerosol can contain harmful and potentially harmful substances, including cancer causing chemicals, heavy metals such as nickel, tin, and lead, volatile organic compounds, and tiny particles that can be inhaled deep into the lungs.[1] Even where some have tried to present vaping as the clean answer to cigarettes, public health authorities have been clear that this does not make e-cigarettes safe.[1]

The pattern here is hard to miss.

Once the world began turning more aggressively against cigarettes, the nicotine industry needed a new format. It needed something modern, something scalable, something that could survive growing hostility toward combustible tobacco. Vaping answered that need. It preserved the central economic engine, nicotine dependence, while changing the outward presentation of the product.

In other words, the nicotine economy did what large industries often do when pressure rises. It rebranded.

That is why the real divide in this category is no longer between cigarettes and vapes. The real divide is between products that continue to revolve around nicotine and products designed to move people away from nicotine altogether.

That distinction is becoming more important, not less.

The World Health Organization states that tobacco kills more than 7 million people each year, with an estimated 1.6 million additional deaths from second hand smoke exposure.[3] WHO also notes that among smokers who are aware of the dangers of tobacco, most want to quit.[3] That is a remarkable and important point. Demand for quitting already exists. The world does not need to create desire to escape nicotine. That desire is already there. The real question is whether the market is offering realistic tools that align with that goal.

This is where the future of the category may begin to separate from its past.

For decades, the dominant response to nicotine addiction was to manage nicotine through alternative formats. But if vaping has shown anything, it is that changing the format does not necessarily solve the problem. Sometimes it simply extends it. A more modern and more direct response may be to remove nicotine from the center of the cessation model entirely.

That is the strategic lane Redwood Scientific Technologies is pursuing through TBX FREE and TBX VAPE FREE. Redwood is developing nicotine free oral thin film technologies designed to align with a broader shift in public health thinking and market demand: the need for approaches that aim to help people move beyond nicotine dependence rather than continue cycling through it in new forms. That positioning does not represent a claim of clinical effectiveness. It reflects alignment with where the problem actually sits today. The modern nicotine crisis is no longer just about cigarettes. It is about nicotine itself, regardless of how polished the device has become.

That is the larger lesson of this 2 part series.

Part 1 showed how nicotine became the invisible engine behind the cigarette business. Part 2 shows how that same engine was carried forward into vaping with a more modern shell. The packaging evolved. The technology evolved. The dependency remained.

And that is why the next real opportunity in smoking and vaping cessation may not come from another nicotine product at all.

It may come from finally treating nicotine as the enemy, not the solution.

Sources and References

[1] U.S. Centers for Disease Control and Prevention, Health Effects of Vaping. “No tobacco products, including e-cigarettes, are safe.” “Most e-cigarettes contain nicotine, which is highly addictive.” The CDC also states that e-cigarette aerosol can contain harmful and potentially harmful substances, including cancer causing chemicals, heavy metals, volatile organic compounds, and tiny particles that can be inhaled deep into the lungs.

[2] U.S. Centers for Disease Control and Prevention, E-Cigarette Use Among Youth. “E-cigarettes are the most commonly used tobacco product among U.S. youth.” The CDC reports that in 2024, 1.63 million U.S. middle and high school students currently used e-cigarettes, and that most middle and high school students who vape want to quit.

[3] World Health Organization, Tobacco Fact Sheet. WHO states that tobacco kills more than 7 million people each year, with an estimated 1.6 million additional deaths from second hand smoke, and notes that among smokers who are aware of the dangers of tobacco, most want to quit.

About Redwood Scientific Technologies, Inc.
Redwood Scientific Technologies, Inc. is focused on developing innovative nicotine free technologies designed to help smokers transition away from combustible cigarettes and nicotine based products. The company’s TBX FREE and TBX VAPE FREE platforms are designed to address the behavioral and sensory aspects of smoking cessation while eliminating nicotine.
Redwood has previously achieved large scale commercial distribution of its oral thin film technologies and continues to advance new solutions designed for the global smoking cessation market. With more than 1 billion smokers worldwide and increasing regulatory pressure on both cigarettes and vaping products, demand for effective nicotine free alternatives continues to grow.
Additional information about Redwood Scientific Technologies can be found at
https://redwoodsci.com

Additional Company Disclosure
Redwood Scientific Technologies, Inc. is currently advancing the development of its nicotine free cessation technologies, including TBX FREE and TBX VAPE FREE. The company is in the process of completing required clinical validation through controlled research protocols.
Redwood’s products are not currently being marketed or sold. The company intends to complete a double blind placebo controlled efficacy study covering both product platforms prior to any commercial launch. These studies are designed to evaluate the effectiveness of the products in supporting smoking and vaping cessation and to provide data suitable for scientific publication.
Until those studies are completed and the company finalizes its clinical and regulatory strategy, Redwood Scientific Technologies does not offer these products for sale.
In addition, Redwood’s commercial strategy is structured as a business to business distribution model. The company does not sell products directly to end users or directly to consumers. Instead, Redwood intends to work through licensed distributors, healthcare partners, and institutional channels for future product distribution.

Forward Looking Statement Notice
Certain statements contained in this article constitute forward looking statements within the meaning of applicable securities laws. These statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. Forward looking statements include, but are not limited to, statements regarding clinical studies, product development, regulatory strategy, commercialization plans, and market opportunities.
Readers and investors should not place undue reliance on forward looking statements, which speak only as of the date of publication.
This article is provided for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy securities.